(Boursier.com) — The 2021 revenues ofIntegragen amounted to 11,324 KE, up 26% compared to the previous year. Excluding the re-invoicing of personnel costs to the parent company (546 KE), turnover amounted to 10,823 KE, i.e. a growth of 20% compared to 2020 (9,000 KE).
Operating expenses amounted to 11,589 KE, up 23% compared to 2020. This increase is explained by various factors including the increase in the cost of consumables, the re-invoicing of personnel costs from the parent company (512 K), the increase in payroll costs following the recruitments made over the last twelve months. Over the period, the average workforce increased from 43 to 49 people. This increase also illustrates the investments in Quality within the framework of the certifications of the Evry laboratory.
The gross operating surplus (EBITDA) is positive at 170 KE against a loss of 28 KE in 2020.
The financial result shows an income of 126 KE in particular following the sale of securities against a loss of 2 KE in 2020.
The exceptional result is a net loss of 197 KE which is mainly explained by restructuring costs.
Research, development and innovation efforts have generated a tax credit of 130 KE compared to 92 KE in 2020.
The 2021 financial year ended with a positive net result of 15 KE in 2021 against a loss of 375 KE in 2020.
A solid balance sheet
IntegraGen’s available cash amounted to 4,781 KE at the end of December 2021 compared to 5,124 KE a year earlier. The change is explained by the flow of current operations, changes in working capital requirements and by investments in quality systems. This cash position includes a State Guaranteed Loan (PGE) of 1,800 KE obtained in the context of the Covid-19 pandemic, the reimbursement of which over a period of 5 years will begin in June this year.
Continued expected growth
IntegraGen intends to pursue revenue growth in 2022 based on the order book to be delivered and the positive trend observed in the market with academic and private clients.
The completed integration within the OncoDNA group confirms IntegraGen’s commercial development prospects outside France.
The available cash will be used to finance operational and investment needs.
©2022 Boursier.com